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Summary: 
Using observational data from COHERE, we emulated a randomized trial which showed that primary 
PcP prophylaxis can be safely withdrawn in virologically suppressed patients on ART, irrespective of 
the CD4 count.  
 
 
 
  
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article/doi/10.1093/cid/ciaa615/5843639 by guest on 25 August 2020
Ac
ce
pte
d M
an
us
cri
pt
 
4 
 
Abstract 
Background 
Using data from the COHERE collaboration, we investigated whether primary prophylaxis for 
Pneumocystis Pneumonia (PcP) might be withheld in all patients on antiretroviral therapy with 
suppressed plasma HIV RNA (≤ 400c/mL) irrespective of CD4 count. 
Methods 
We implemented an established causal inference approach whereby observational data is used to 
emulate a randomised trial. Patients taking PcP prophylaxis were eligible for the emulated trial if their 
CD4 count was ≤ 200 cells/µL in line with existing recommendations. We compared the following 
two strategies for stopping prophylaxis: i.) when CD4 count was above 200 cells/µL for more than 3 
months, or ii.) when the patient was virologically suppressed (two consecutive HIV RNA ≤ 400c/mL). 
Patients were artificially censored if they did not comply with these stopping rules. We estimated the 
risk of primary PcP in patients on ART, using the hazard ratio to compare the stopping strategies by 
fitting a pooled logistic model, including inverse probability weights to adjust for the selection bias 
introduced by the artificial censoring. 
Results 
4’813 patients (10’324 person years) complied with eligibility conditions for the emulated trial. With 
primary PcP diagnosis as endpoint, the adjusted hazard ratio (aHR) indicated a slightly lower, but not 
statistically significant, different risk for the strategy based on viral suppression alone compared to the 
existing guidelines  (aHR 0.8 with 95% CI [0.6, 1.1], p = 0.2).  
 
Conclusions 
The study suggests that primary PcP prophylaxis might be safely withheld in confirmed ART-
virologically suppressed patients, regardless of their CD4 count. 
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1. Introduction 
Pneumocystis pneumonia (PcP) is an opportunistic disease contracted by individuals having a 
weakened immune system, and it remains one of the most frequent AIDS defining diagnoses in 
resource rich countries in late presenters [1, 2].  
People diagnosed with HIV and with low CD4 lymphocyte counts are at risk of developing PcP and 
should be prescribed combination antiretroviral treatment (ART) in order to suppress plasma viral 
load, and prophylactic treatments [3, 4]. Adding prophylactic treatment, apart from increasing pill 
burden, could cause adverse events and potentially increase the risk of antibacterial resistance due to 
prolonged usage. 
The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord 
was a project-based collaboration which comprised 40 adult, paediatric, and mother/child HIV cohorts 
across Europe. The collaboration, which was active from 2005-2015, allowed for annual coordinated 
data collection via a centrally-developed standardized operating procedure.  The COHERE 
collaboration addressed novel research questions that could not be studied adequately in individual 
cohorts (http://www.cohere.org). 
Previous analyses conducted on COHERE suggested that primary PcP prophylaxis can be safely 
withdrawn in patients with CD4 counts of 100-200 cells/µL if HIV-RNA is suppressed [5]. A more 
recent study added new findings, indicating that PcP incidence off prophylaxis was below 1/100 
person years for virologically suppressed individuals with a CD4 count above 100 cells/µL, 
concluding that primary (and secondary) prophylaxis might not be needed in such cases [6]. However, 
it remains to be determined if PcP prophylaxis might be fully withdrawn for patients with consistently 
suppressed HIV viral load (VL), irrespective of CD4 count.  
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The current EACS guidelines that are, at least partially, based on the results from these studies, 
recommend the following rules for stopping primary PcP prophylaxis (page 105 of [7]): 
“Stop: if CD4 count > 100 cells/μL and HIV-VL undetectable for over 3 months,” 
whereas the US NIH guidelines state [8]: 
“Primary Pneumocystis prophylaxis should be discontinued in adult and adolescent patients who have 
responded to ART with an increase in CD4 counts from <200 cells/mm3 to >200 cells/mm3 for >3 
months.” 
The gold standard for estimating the risk of PcP would be to conduct a randomized trial. However, 
due to the low levels of PcP diagnoses for patients on ART, a randomised trial would be prohibitive 
both in terms of time and cost. Given the wealth of new data available in COHERE since initial 
studies focusing on PcP were carried out, the goal of our study was to investigate whether PcP 
prophylaxis might be withheld in all patients on antiretroviral therapy with suppressed plasma HIV 
RNA (<400c/mL). We use the data to compare the risk of two PcP prophylaxis stopping strategies; 1.) 
the existing guidelines with a CD4 count of 200 as threshold, versus 2.) a new strategy based solely 
on confirmed viral suppression. We estimate the risk of primary PcP in patients on ART by applying 
the established causal inference approach in which observational data are used to emulate a 
hypothetical randomised trial comparing the two prophylaxis stopping strategies (e.g. [9, 10, 11, 12]). 
This approach was pursued since the incidence of PcP for patients on cART is very low, and therefore 
a randomised trial would be prohibitive both in terms of time and cost. An “emulated trial” using 
observational data offers a viable alternative to estimate the risk of a proposed new treatment strategy. 
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2. Methods 
2.1. Hypothetical target trial 
We emulated a pragmatic randomized controlled trial using observational data, and the natural 
starting point for this approach is to first define the hypothetical target trial to investigate the 
hypothesis. Since there is some degree of inconsistency between the current guidelines, in the 
interests of greater applicability for our study results, we chose a least common denominator of both 
the EACS and NIH guidelines with just the CD4 threshold of 200 cells/μL as criteria for stopping PcP 
prophylaxis.  
The target trial is defined as a two arm, open label study comparing the risk of two different strategies 
for taking and stopping PcP prophylaxis. HIV infected individuals are eligible to enter the 
hypothetical target trial if i.) they began follow-up in their cohort after 1998, ii.) they started ART on 
or after this date (defined as any combination of 3 or more antiretrovirals of any type), iii.) are 16 
years or older, iv.) have no history of previous PCP, and finally, v.) they are taking PcP prophylaxis in 
line with existing recommendations, (i.e. they have a CD4 count of less than <200 cells/µL).  
If eligible, patients are randomized to one of the two PcP prophylaxis strategies:  
- Strategy 1 (current guidelines): Continue taking PcP prophylaxis if CD4 <200 cells/µL, and 
stop if CD4 increases from <200 cells/µL to >200 cells/µL for >3 months. Patients re-start 
prophylaxis if CD4 <200 cells/µL. 
- Strategy 2 (new): Continue taking PcP prophylaxis if HIV RNA ≥400 c/ml, and stop if the 
patient has confirmed viral suppression, defined as two consecutive HIV RNA measurements 
<400 c/ml in approximately a 3 month period. (This lower limit of quantification was 
implemented to account for earlier follow-up visits in which detection thresholds were higher 
than the current 20 c/ml). Patients re-start when they are no longer virologically suppressed, 
defined as having two consecutive HIV RNA measurements ≥400 c/ml. 
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Patients continue taking prophylaxis on the respective strategy until the above stopping conditions for 
their randomised arm have been met, and then they stop taking prophylaxis. They may re-start 
prophylaxis also according the rules for the respective strategy. Individuals not complying with the 
stopping and re-starting rules of their randomized arm are considered to be deviating from the trial 
protocol. This process is summarised graphically in Figure S1 of Appendix A in the supplementary 
material. 
Participants continue in the trial until they are diagnosed with PcP (the endpoint), drop-out (e.g. due to 
protocol non-compliance, or adverse effects from treatment), die, or the administrative end of follow-
up is reached (5 years).  
The next section summarises the steps taken to emulate the hypothetical target trial using 
observational data. 
2.2. Emulated trial 
Study population 
To emulate the target trial, we included data from the 2015 merger of the COHERE database from 23 
of HIV cohorts for the period 2009 up to 1st quarter 2015. All patients were therefore treated when the 
guidelines for PcP prophylaxis were based only on the CD4 count threshold of 200 cells/μL. 
Information on patient characteristics (age, gender, geographical origin, and transmission category), 
use of ART (type of regimes, and dates of start and discontinuation), CD4 cell counts and plasma 
HIV-RNA over time and their dates of measurement, AIDS-defining conditions, and recorded drop-
outs and deaths was recorded. We selected patients in COHERE compliant with the same eligibility 
criteria as in the target trial defined in the previous section. Specifically, a patient was deemed 
eligible at the first visit at which the CD4 count was <200 cells/µL and they were taking PcP 
prophylaxis (in line with current guidelines). Baseline patient characteristics were defined as recorded 
at this visit (refer to Table 2). All subsequent visits for such patients were included as the follow-up 
for that specific patient. It is assumed that patients continue ART treatment once started, irrespective 
of any intermittent periods of non-adherence. 
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A total of 4’813 patients with 94’825 follow-up visits were eligible for the emulated trial (refer to 
Table 1, Appendix B, “Data set definition”, and Consort-type diagram in Figure S2). We defined the 
point of randomisation for the emulated trial to be the first time point at which the eligibility criteria 
were met, defining this as “time 0” for the particular patient, and measuring the time in months from 
this starting point.  
Randomisation and artificial censoring 
At the point of randomization, all patients are eligible for both of the stopping strategies. Therefore, 
we adopt the approach set-out, for example, in Cain et al. [10], and replicate all patients, so that each 
patient is on both arms at the point of randomization (time zero). This cloning process means that at 
time 0 there are no differences between the patients assigned to the strategies. (However, this does 
mean that we have to compensate in the analysis for cloning the patients in this way – refer to 
“statistical methods”). 
As in the target trial, follow-up visits from patients are included in the emulated trial until they are 
diagnosed with PcP or the administrative end of follow-up is reached (5 years). Visits are included for 
patients up to point they drop-out (for any reason) or die, after which they are censored as usual in a 
time-to-event analysis. 
In addition, a patient can be “artificially censored” for two reasons: Firstly, if they stop taking 
prophylaxis before meeting the defined stopping criteria for the assigned strategy, and secondly, if 
they keep taking prophylaxis when they should have stopped according to their strategy. So, for 
example, a patient on Strategy 1 who does not stop prophylaxis when her CD4 count >200 cells/µL is 
artificially censored. Analogously, a patient on the new Strategy 2 is artificially censored if he/she is 
virologically suppressed, and does not stop taking prophylaxis. As in the target trial, patients can have 
multiple periods of being on an off prophylaxis so long as they are compliant with their assigned 
strategy. A comparison of the target and emulated trials, and their differences is presented in 
Appendix A Table S1 in the supplementary material.  
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Statistical methods 
The longitudinal data set was expanded to have patient follow-up on a monthly basis (refer to 
Appendix C). We fitted a pooled logistic regression model to this expanded data set to estimate the 
hazard ratio comparing the risk of the two treatment strategies. This approach provides a reasonable 
approximation to the Cox proportional hazards model when the risk of an event is small in any 
particular time window [13, 14].  
To model the baseline hazard, we included “time” (measured in months from time 0 for each patient), 
along with its square and cubic terms. The model included an indicator variable for the strategy, along 
with an interaction term between stopping strategy and time to allow for non-proportional hazards, 
and the following baseline variables; gender, baseline age, geographical origin (Europe (reference), 
Africa, Asia, Latin America, North Africa and Middles East), transmission mode (Heterosexual 
(reference), MSM, IDU, Other), baseline CD4 (and its square), cohort, baseline HIV RNA (and its 
square), calendar year at time 0 for this patient (to take into account changes in guidelines), indicator 
variable for censoring due to death or drop-out, and a variable defining the percentage of post-
baseline (i.e. post-randomization) follow-up time on ART. Where CD4 counts, HIV RNA 
measurements and details of prophylaxis were not available for a patient in a particular month, we 
used the last observation carried forward to impute the missing values. Due to the relatively low 
(<5%) number of missing records for baseline covariates, only the complete records were analyzed. 
Furthermore, we included inverse probability weights in the model to compensate for potential 
selection bias from artificial censoring. Details of the modelling approach, along with a subgroup 
analysis investigating “grace periods” for stopping prophylaxis are defined in Appendix C. 
All analyses were carried out in R version 3.2.4 [15], using the function svyglm in package “survey” 
to calculate robust sandwich errors from logistic models. Throughout we used a level of 0.05 as 
statistically significant. 
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Patient and Public Involvement 
There was no patient or public involvement with regards to the design, conduct, reporting or 
dissemination of the research. 
Ethical approval 
Ethical approval was applied for and granted for the research from the appropriate body in the host 
country of the cohort contributing the data to COHERE. 
3. Results 
There were 4’813 patients included in the emulated trial with 52 (1.1%) PcP diagnoses (refer to Table 
1). The median time between HIV RNA measurements was 2.8 months (inter-quartile range (IQR) 
[1.5, 3.7]). The total follow-up time was 10’324 person years (py) on Strategy 1 (existing prophylaxis 
guidelines, median 4.3 py per patient, IQR [1.3, 5.1],) and 10’324 py on Strategy 2 (based on viral 
suppression only, 2.9 py IQR [0.9, 5.1]). 
A crude rate comparison considering those patients still in follow-up after 60 months implied 
treatment strategy 2 had a lower rate of PcP diagnosis than Strategy 1 (2.1% vs 1.3%, p=0.03). 
However, this difference was not mirrored in the unadjusted incidence rates (Strategy 1: 4.2 events 
per 1000py, 95% confidence interval (CI) [3.1, 5.3] vs Strategy 2: 4.9 [3.6, 6.3, p=0.4). 
After fitting the pooled logistic regression model including all person months, adjusting for baseline 
factors and including the inverse probability weights, the hazard ratio (HR) for the first 5 years of 
follow-up was 0.8 (95% confidence interval (CI) [0.6, 1.1], p=0.2), indicating a marginal, but not 
statistically significant, lower risk on the stopping Strategy 2 (see Table 2). In the adjusted model, 
none of the covariates were significant at the 5% level, except for the variable defining the post-
baseline ART adherence (p=0.02). With this latter point in mind, we performed a further analysis 
limited to patients with post-baseline visits exclusively on ART, censoring patients at the first visit 
that they were no longer on ART. Fitting the analysis model to this smaller data set of 4’089 patients, 
the adjusted hazard ratio attenuated slightly (HR 0.9 [0.6, 1.3], p=0.6; see Figure 1).  
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Using the fitted parametric model we were able to estimate the survival probability over the course of 
the hypothetical trial period of 5 years (see Figure S3 in the supplementary material), and to estimate 
the difference in absolute risk between the two treatment strategies (i.e. Strategy 1 – Strategy 2) after 
5 years (risk difference: 0.00, 95% CI [-0.01, 0.01]). 
4. Discussion 
Comparison of the PcP prophylaxis stopping strategies using a suitably adjusted model indicated that 
the risk using only confirmed and maintained plasma HIV RNA viral suppression on ART as the 
criteria for stopping PcP prophylaxis is the same as that for the current NIH guidelines using a CD4 
count threshold of 200 cells/µL. We defined viral suppression to be at least two consecutive 
measurements over approximately a 3-month period. The newest EACS guidelines are less 
conservative than the prophylaxis stopping rules we used as the comparator in our study, and 
therefore the study results presented here would tend to underestimate the potential benefit of a 
stopping strategy based solely on viral suppression.  
A previous study using the COHERE data indicated that discontinuing or withholding primary or 
secondary prophylaxis in patients with CD4 counts above 100cells/µL, suppressed viral load on ART, 
and without other immunodeficiencies, is safe [16]. To our knowledge, the present study involves the 
largest cohort of patients comparing the effects of stopping primary PCP prophylaxis in virologically 
suppressed patients irrespective of CD4 counts. 
Our study extends results from smaller cohorts [17, 18, 19], a randomized trial [20] and two reviews 
[21, 22]. In recent years, many physicians have stopped prescribing PcP prophylaxis in patients with 
suppressed viraemia on ART, even with low CD4 counts [23], and our results highlight an acceptable 
low risk associated with such an approach. 
Previous studies have used the trial emulation approach [9, 10, 11], and our study highlights the 
generalisability of such methods. Whilst using observational data in this way remains rather novel, the 
American Society of Clinical Oncology recently provided a cautious endorsement explaining 
“observational studies can also answer or inform questions that either have not been or cannot be 
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answered by RCTs” ([24] quoting from [25]). Our emulated trial aimed to mimic the design of a 
randomised trial as closely as possible, and thereafter to be precise and open about the limitations of 
the adopted approach. We make the assumption of no unmeasured confounding throughout - 
unfortunately, there is no definitive way of determining if this assumption is justified.  
Our study has a number of other limitations. We emulate a target trial and being unblinded brings 
with it drawbacks; we cannot rule out potential behavioural changes associated with a patient 
knowing that he/she is on prophylaxis. The presence of undiagnosed PCP at the time the trial is 
started is a potential risk in both a hypothetical target and emulated trial. In our observational data, 
certain physicians may be more, or less, cautious about prescribing prophylaxis perhaps depending on 
unrecorded characteristics that may influence the outcome. We restricted follow-up to 5 years to 
mirror a realistic trial, but this means our risk analysis is accordingly limited to this time period. In 
terms of the general application of our results, it is important to note that whilst data from 23 
European cohorts was included in the analysis, two of the large European countries (France, UK) 
were potentially under-represented in the analysis. In addition, our study does not include participants 
under 16 years of age, and therefore the conclusions are not generalizable to children living with HIV. 
Finally, and perhaps most importantly, there were 36% of patients (N=1752) with a CD4 count of 
≤100 cells/μL, and 16% of patients (N=787) with a CD4 count of ≤50 cells/μL, at baseline in the 
analysis. However, these patients contributed over-proportionally to the number of PcP diagnoses 
with 23/52 (44%) and 12/52 (23%) respectively. Notwithstanding the results presented from this 
study, clinicians may require further reassurance of our findings before definitely choosing to stop 
prophylaxis for these higher risk groups. 
From a methodological standpoint, we use a single imputation method (LOCF) to estimate the 
trajectory of the CD4 and RNA measurements over time. This has the same potential drawbacks of 
other single imputation methods in terms of variance estimation and potential bias. An alternative 
would be to multiply impute the time varying covariates [26], and this is an area for potential further 
study. Furthermore, since Inverse Probability Weighting inherently assumes patients are censored at 
random, a sensitivity analysis might be considered to investigate potentially non-informative 
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censoring [27]. In conclusion, HIV replication measured as plasma HIV-RNA is a major contributor 
to the risk factor of developing primary PcP. In virologically suppressed patients on ART, irrespective 
of CD4 levels, the risk of PcP is marginally lower using viral suppression alone, compared to when 
prophylaxis is taken based on the CD4 count threshold according to current guidelines. The study 
suggests that primary PcP prophylaxis might be safely withheld in patients on ART with confirmed 
plasma viral suppression, regardless of their CD4 count. 
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Tables and Figures 
Table 1: Baseline characteristics for patient in the emulated trial 
 Overall No PcP diagnosis PcP diagnosis p-value 
Number of patients 4’813 4’761 52 (1.1%) - 
Female (%) 1195 (24.8%) 1’182 (24.8%) 13 (25.5%) 0.99 
Age in years (median [IQR]) 40 [35, 47] 40 [25, 47] 40 [33, 46] 0.58 
Geographical orgin    0.54 
  Europe 3'938 (81.8%) 3'895 (81.8%) 43 (84.3%)  
  Africa 482 (10.0%) 478 (10.0%) 4 (7.8%)  
  Asia 83 (1.7%) 82 (1.7%) 1 (2.0%)  
  Latin America 236 (4.9%) 235 (4.9%) 1 (2.0%)  
  North Africa and Middle 
East 
74 (1.5%) 72 (1.5%) 2 (3.9%)  
HIV transmission mode (%)    0.44 
  MSM  1’606 (33.4%) 1’586 (33.3%) 20 (39.2%)  
  Heterosexual 1’833 (38.1%) 1’815 (38.1%) 18 (35.3%)  
  IDU 1’155 (24.0%) 1’146 (24.1%) 9 (17.6%)  
  Other 219 (4.6%) 215 (4.5%) 4 (7.8%)  
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CD4 (cells/μL) 130 [77, 169] 130 [77, 169] 120 [53, 159] 0.11 
HIV RNA (copies/ml) 1460 [107, 65000] 1402 [102, 63816] 46700 [540, 227600] <0.001 
Calendar year at start of 
emulated trial 
2003 [1999, 2008] 2003 [1999, 2008] 2002 [1998, 2006] 0.18 
% of follow-up on ART 84% [41%, 100%] 84% [41%, 100%] 100% [84%, 100%] <0.001 
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Table 2: Patient numbers at baseline and at the end of follow-up (60 months), along with crude rate 
and incidence comparisons of strategies, and hazard ratio estimates from the pooled logistic model; 
hazard ratios < 1 indicate that the new strategy using viral suppression as criteria reduces risk 
compared to the existing strategy based on CD4 count. 
  Strategy 1 
Existing 
prophylaxis 
guidelines 
Strategy 2 
New 
p-value 
Baseline 
(month 0) 
Total patients 4’813 4’813  
Follow-up Died 183 (3.8%) 158 (3.3%)  0.2 
Follow-up Dropped-out 233 (4.8%) 216 (4.5%) 0.4 
Follow-up Artificially censored 2’319 (48.2%) 1’006 (20.9%) < 0.001 
End of study 
(month 60) 
Total patients 
off PcP prophylaxis 
on PcP prophylaxis 
2’494 
1’140 (45.7%) 
1’354 (54.3%) 
3’807 
932 (24.5%) 
2’875 (75.5%) 
 
<0.001 
 
Rate 
comparison 
(month 60) 
PcP diagnoses 
off PcP pro hylaxis 
on PcP prophylaxis 
52 (2.1%) 
17 (1.5%) 
35 (2.6%) 
51 (1.3%) 
16 (1.7%) 
35 (1.2%) 
0.03 
0.7 
0.001 
Incidence 
comparison 
Total follow-up (py) 
off PcP prophylaxis 
on PcP prophylaxis 
12’388 
4’439 (35.8%) 
7’749 (64.2%) 
10’324 
3’762 (36.4%) 
6’562 (63.6%) 
 
Median follow-up per patient (py) [IQR] 
off PcP prophylaxis 
on PcP prophylaxis 
4.3 [1.3, 5.1] 
5.0 [3.7, 5.2] 
1.6 [0.7, 3.1] 
2.9 [0.9, 5.1] 
5.0 [2.4, 5.2] 
1.4 [0.5, 4.7] 
<0.001 
0.01 
0.02 
Incidence (per 1000 py) [95% CI] 4.2 [3.1, 5.3] 4.9 [3.6, 6.3] 0.4 
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off PcP prophylaxis 
on PcP prophylaxis 
3.8 [2.0, 5.7] 
4.5 [3.0, 6.0] 
4.3 [2.2, 6.3] 
5.3 [3.6, 7.1] 
0.8 
0.5 
Hazard ratio 
 
Primary Endpoint (hazard ratio) 
Unadjusted analysis without IPW* 
Unadjusted analysis with IPW* 
Adjusted analysis without IPW** 
Adjusted analysis with IPW** 
 
Reference 
Reference 
Reference 
Reference 
 
1.2 [1.0, 1.3] 
0.9 [0.6, 1.1] 
1.1 [1.0, 1.3] 
0.8 [0.6, 1.1] 
 
0.04 
0.2 
0.2 
0.2 
Absolute risk 
difference 
(60 months) 
Secondary endpoint  
Absolute risk difference 
 
0.99 [0.97, 0.99] 
 
0.99 [0.97, 0.99] 
0.00 [-0.01, 0.01] 
 
Hazard ratio 
 
Further Analyses 
Adjusted and including IPW** 
1.) 100% ART adherence 
2.) No grace period+ 
3.) Grace period 6 months+ 
 
 
Reference 
Reference 
Reference 
 
 
0.9 [0.6, 1.3] 
0.6 [0.3, 1.0] 
0.8 [0.7, 1.0] 
 
 
0.6 
0.04 
0.05 
IQR: Inter-quartile range, py: person years, CI: confidence interval; IPW: inverse probability weighting; * Unadjusted model 
has PcP diagnosis as dependent variable and as independent variables, indicator variables for the strategy along with time, 
time2 and time3. Interactions between time (and its square and cube) and the strategy were not significant at the 5% level; ** 
Adjusted model contains the same terms as the unadjusted model, along with the baseline covariates age, age2, gender, mode 
of transmission, geographical origin, cohort, CD4, CD42, log10 HIV RNA, log10 HIV RNA2, calendar year at time0 for each 
patient, indicator variables for death and drop-out, and the percentage post-baseline follow-up time on ART; + Refer to 
subgroup analysis at the end of Appendix C. 
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Figure 1 Legend:   
Hazard ratio estimates and 95% confidence intervals from the fitted unadjusted and adjusted models 
with and without inverse probability weighting (IPW); hazard ratios < 1 indicate that the new strategy 
using viral suppression as criteria reduces risk compared to the existing strategy based on CD4 count. 
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Figure 1 
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